Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

Delayed Quote. Delayed  - 09/23 05:35:09 pm
44 GBp   -1.12%
09/13 VERNALIS : Notice of Full Year Results
09/07 VERNALIS : FDA accepts CCP-07 NDA for full review
09/06 VERNALIS : Says New Drug Application For CCP-07 Accepted In US
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Vernalis plc
Researches and develops pharmaceutical products

Vernalis Plc engages in the research, development, and commercialization of pharmaceutical products under the Tuzistra XR brand.

The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, United Kingdom.

Number of employees : 91 persons.
Sales per Businesses
2015
GBP (in Million)%
Pharmaceuticals13.26100%
Sales per Regions
2015
GBP (in Million)%
Rest of Europe10.2577.4%
Rest of the World2.3217.5%
North America0.6695%
United Kingdom0.0160.1%
Managers
NameAgeSinceTitle
Ian Garland50-Chief Executive Officer & Executive Director
Peter John Fellner, PhD732003Non-Executive Chairman
David MacKney48-Chief Financial Officer & Executive Director
Pascal Borderies, MD-2014Senior Vice President-Medical Affairs
Carol C. Ferguson692003Senior Independent Non-Executive Director
Nigel Sheail502011Independent Non-Executive Director
Ian David Gilham, PhD562015Independent Non-Executive Director
Lisa Amster Schoenberg, MBA492015Non-Executive Director
Kevin Kissane602010Secretary & General Counsel
Mike Wood-2004Research Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 526,202,417 520,295,370 98.9% 0 0.0% 98.9%
Shareholders
NameEquities%
Invesco Asset Management Ltd. 194,441,770 37.0%
Woodford Investment Management LLP 148,077,297 28.1%
GAM London Ltd. 40,715,903 7.74%
Legal & General Investment Management Ltd. 28,672,162 5.45%
Aviva Investors Global Services Ltd. 27,065,665 5.14%
Rothschild Bank AG 12,129,000 2.31%
OppenheimerFunds, Inc. 7,550,000 1.43%
Majedie Asset Management Ltd. 5,991,000 1.14%
EdenTree Investment Management Ltd. 4,750,000 0.90%
River & Mercantile Asset Management LLP 3,137,000 0.60%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Advertisement
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
VERNALIS PLC-37.92%300
INCYTE CORPORATION-17.95%16 728
CELLTRION, INC.--.--%11 664
LONZA GROUP AG13.18%10 059
QUINTILES TRANSNATIONA..15.66%9 453
SEATTLE GENETICS, INC.24.40%7 845
ALKERMES PLC-37.54%7 514
ALNYLAM PHARMACEUTICAL..-19.73%6 478
QIAGEN NV-3.58%6 391
UNITED THERAPEUTICS CO..-18.77%5 530
IONIS PHARMACEUTICALS ..-43.29%4 247
ICON PLC-1.57%4 242
ACADIA PHARMACEUTICALS..-1.88%4 189
BIO-TECHNE CORP20.38%4 041
CHARLES RIVER LABORATO..2.95%3 914
PAREXEL INTERNATIONAL ..2.97%3 730
PRA HEALTH SCIENCES IN..23.48%3 406
GALAPAGOS12.37%3 306
INTREXON CORP-9.09%3 243
BB BIOTECH AG-12.49%2 941
NEKTAR THERAPEUTICS11.28%2 564
Sector Biotechnology & Medical Research - NEC
Vernalis plc : Connections
Biosurfit SA
The Institute of Chartered Accountants of Scotland
Bayer HealthCare
Multiplicom NV
Concepta Diagnostics Ltd.
Chartered Accountants Compensation Scheme Ltd.
Stowheath Ltd.
Company contact information
Vernalis Plc
100 Berkshire Place
Wharfedale Road
Winnersh, Berkshire RG41 5RD

Phone : +44.118.938.0000
Fax : +44.118.938.0001
Web : www.vernalis.com
© 2016 People , Fundamentals and Ownership